These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34680440)

  • 1. An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells.
    Hsu LJ; Liu CL; Kuo ML; Shen CN; Shen CR
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.
    Shankar K; Capitini CM; Saha K
    Stem Cell Res Ther; 2020 Jun; 11(1):234. PubMed ID: 32546200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell-derived induced pluripotent stem cell library.
    Du W; Cui L; Zhang J; Zhang H; Liu R; Yang W; Zhang Y
    FEBS Open Bio; 2022 Oct; 12(10):1771-1781. PubMed ID: 35747945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
    Flahou C; Morishima T; Takizawa H; Sugimoto N
    Front Immunol; 2021; 12():662360. PubMed ID: 33897711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
    Zhu H; Kaufman DS
    Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.
    Zeng J; Tang SY; Toh LL; Wang S
    Stem Cell Reports; 2017 Dec; 9(6):1796-1812. PubMed ID: 29173894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
    Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
    Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
    Nianias A; Themeli M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
    Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
    Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
    Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
    Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
    Mehra V; Chhetri JB; Ali S; Roddie C
    Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products.
    Chung L; Cogburn LA; Sui L; Dashnau JL
    Cytotherapy; 2022 Jul; 24(7):733-741. PubMed ID: 35461759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.